2 weeks Ago By Defense World Staff
Rhumbline Advisers trimmed its position in Ovid Therapeutics Inc. ( NASDAQ:OVID – Free Report ) by 15.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The fund owned 69,733 shares of the company’s stock after selling 12,851 shares during the quarter. Rhumbline Advisers owned about 0.10% of Ovid Therapeutics worth $54,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also modified their holdings of OVID. Price T Rowe Associates Inc. MD raised its holdings in Ovid Therapeutics by 22.
1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,396 shares of the company’s stock worth $54,000 after acquiring an additional 3,145 shares during the period.
China Universal Asset Management Co. Ltd. increased its stake in shares of Ovid Therapeutics by 66.
0% in the first quarter. China Universal Asset Management Co. Ltd.
now owns 13,579 shares of the company’s stock worth $41,000 after purchasing an additional 5,401 shares during the period. Empowered Funds LLC lifted its position in shares of Ovid Therapeutics by 8.1% during the 1st quarter.
Empowered Funds LLC now owns 128,070 shares of the company’s stock worth $391,000 after purchasing an additional 9,625 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Ovid Therapeutics by 74.7% during the 1st quarter.
BNP Paribas Financial Markets now owns 32,162 shares of the company’s stock worth $98,000 after purchasing an additional 13,756 shares during the last quarter. Finally, FFT Wealth Management LLC boosted its stake in Ovid Therapeutics by 18.2% during the 2nd quarter.
FFT Wealth Management LLC now owns 489,552 shares of the company’s stock valued at $377,000 after purchasing an additional 75,530 shares during the period. 72.24% of the stock is owned by institutional investors.
Analysts Set New Price Targets Several brokerages have commented on OVID. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Ovid Therapeutics in a research report on Monday.
B. Riley cut their target price on shares of Ovid Therapeutics from $9.00 to $3.
00 and set a “buy” rating for the company in a research note on Tuesday, June 18th. Oppenheimer lowered shares of Ovid Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 18th. BTIG Research dropped their price objective on shares of Ovid Therapeutics from $11.
00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, June 18th. Finally, William Blair upgraded shares of Ovid Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.
Two analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.
70. Ovid Therapeutics Price Performance NASDAQ:OVID opened at $1.18 on Tuesday.
The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.73 and a current ratio of 5.
73. The company has a 50-day moving average of $1.09 and a 200-day moving average of $1.
97. Ovid Therapeutics Inc. has a 52 week low of $0.
68 and a 52 week high of $4.10. The company has a market capitalization of $83.
72 million, a price-to-earnings ratio of -1.62 and a beta of 0.42.
Ovid Therapeutics ( NASDAQ:OVID – Get Free Report ) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.
22) by $0.34. The firm had revenue of $0.
17 million during the quarter, compared to analyst estimates of $0.14 million. Ovid Therapeutics had a negative net margin of 5,237.
15% and a negative return on equity of 33.40%. As a group, equities research analysts anticipate that Ovid Therapeutics Inc.
will post -0.49 earnings per share for the current fiscal year. Ovid Therapeutics Company Profile ( Free Report ) Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. Further Reading Five stocks we like better than Ovid Therapeutics What does consumer price index measure? TJX Stock: A Buying Opportunity Before the Holiday Rush What Are Some of the Best Large-Cap Stocks to Buy? Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge Special Purpose Acquisition Company (SPAC) What You Need to Know Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
